Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Goodwill (2020 - 2023)

Insight Molecular Diagnostics (IMDX) has disclosed Goodwill for 4 consecutive years, with $9.5 million as the latest value for Q3 2023.

  • Quarterly Goodwill fell 49.15% to $9.5 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Sep 2023, down 49.15% year-over-year, with the annual reading at $9.5 million for FY2022, 49.15% down from the prior year.
  • Goodwill hit $9.5 million in Q3 2023 for Insight Molecular Diagnostics, roughly flat from $9.5 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $24.2 million in Q2 2021 to a low of $9.2 million in Q1 2020.
  • Historically, Goodwill has averaged $13.4 million across 4 years, with a median of $9.5 million in 2022.
  • Biggest five-year swings in Goodwill: surged 163.82% in 2021 and later crashed 49.15% in 2022.
  • Year by year, Goodwill stood at $9.2 million in 2020, then surged by 103.37% to $18.7 million in 2021, then plummeted by 49.15% to $9.5 million in 2022, then changed by 0.0% to $9.5 million in 2023.
  • Business Quant data shows Goodwill for IMDX at $9.5 million in Q3 2023, $9.5 million in Q2 2023, and $9.5 million in Q1 2023.